Drugs That Bind to α-Synuclein: Neuroprotective or Neurotoxic?
Identifieur interne : 000534 ( PubMed/Checkpoint ); précédent : 000533; suivant : 000535Drugs That Bind to α-Synuclein: Neuroprotective or Neurotoxic?
Auteurs : Joe Kakish ; Dongsoo Lee ; Jeremy S. LeeSource :
- ACS chemical neuroscience [ 1948-7193 ] ; 2015.
English descriptors
- KwdEn :
- MESH :
- chemical , drug effects : alpha-Synuclein.
- chemical , metabolism : alpha-Synuclein.
- chemical , therapeutic use : Neuroprotective Agents.
- drug effects : Protein Binding.
- drug therapy : Neurotoxicity Syndromes, Parkinson Disease.
- metabolism : Parkinson Disease.
- Animals, Humans, Molecular Conformation.
Abstract
The misfolding of α-synuclein is a critical event in the death of dopaminergic neurons and the progression of Parkinson's disease. Drugs that bind to α-synuclein and form a loop structure between the N- and C-terminus tend to be neuroprotective, whereas others that cause a more compact structure tend to be neurotoxic. The binding of several natural products and other drugs that are involved in dopamine metabolism were investigated by nanopore analysis and isothermal titration calorimetry. The antinausea drugs, cinnarizine and metoclopramide, do not bind to α-synuclein, whereas amphetamine and the herbicides, paraquat and rotenone, bind tightly and cause α-synuclein to adopt a more compact conformation. The recreational drug, cocaine, binds to α-synuclein, whereas heroin and methadone do not. Metformin, which is prescribed for diabetes and is neuroprotective, binds well without causing α-synuclein to adopt a more compact conformation. Methylphenidate (ritalin) binds to sites in both the N- and C-terminus and causes α-synuclein to adopt a loop conformation. In contrast, amphetamine only binds to the N-terminus. Except for cinnarizine and metoclopramide, there is a good correlation between the mode of binding to α-synuclein and whether a drug is neuroprotective or neurotoxic.
DOI: 10.1021/acschemneuro.5b00172
PubMed: 26378986
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26378986Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drugs That Bind to α-Synuclein: Neuroprotective or Neurotoxic?</title>
<author><name sortKey="Kakish, Joe" sort="Kakish, Joe" uniqKey="Kakish J" first="Joe" last="Kakish">Joe Kakish</name>
<affiliation><nlm:affiliation>Department of Biochemistry, University of Saskatchewan , 107 Wiggins Road, Saskatoon, Canada , S7N 0W0.</nlm:affiliation>
<wicri:noCountry code="subField">S7N 0W0</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Lee, Dongsoo" sort="Lee, Dongsoo" uniqKey="Lee D" first="Dongsoo" last="Lee">Dongsoo Lee</name>
<affiliation><nlm:affiliation>Department of Biochemistry, University of Saskatchewan , 107 Wiggins Road, Saskatoon, Canada , S7N 0W0.</nlm:affiliation>
<wicri:noCountry code="subField">S7N 0W0</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Lee, Jeremy S" sort="Lee, Jeremy S" uniqKey="Lee J" first="Jeremy S" last="Lee">Jeremy S. Lee</name>
<affiliation><nlm:affiliation>Department of Biochemistry, University of Saskatchewan , 107 Wiggins Road, Saskatoon, Canada , S7N 0W0.</nlm:affiliation>
<wicri:noCountry code="subField">S7N 0W0</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26378986</idno>
<idno type="pmid">26378986</idno>
<idno type="doi">10.1021/acschemneuro.5b00172</idno>
<idno type="wicri:Area/PubMed/Corpus">000354</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000354</idno>
<idno type="wicri:Area/PubMed/Curation">000354</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000354</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000354</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000354</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Drugs That Bind to α-Synuclein: Neuroprotective or Neurotoxic?</title>
<author><name sortKey="Kakish, Joe" sort="Kakish, Joe" uniqKey="Kakish J" first="Joe" last="Kakish">Joe Kakish</name>
<affiliation><nlm:affiliation>Department of Biochemistry, University of Saskatchewan , 107 Wiggins Road, Saskatoon, Canada , S7N 0W0.</nlm:affiliation>
<wicri:noCountry code="subField">S7N 0W0</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Lee, Dongsoo" sort="Lee, Dongsoo" uniqKey="Lee D" first="Dongsoo" last="Lee">Dongsoo Lee</name>
<affiliation><nlm:affiliation>Department of Biochemistry, University of Saskatchewan , 107 Wiggins Road, Saskatoon, Canada , S7N 0W0.</nlm:affiliation>
<wicri:noCountry code="subField">S7N 0W0</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Lee, Jeremy S" sort="Lee, Jeremy S" uniqKey="Lee J" first="Jeremy S" last="Lee">Jeremy S. Lee</name>
<affiliation><nlm:affiliation>Department of Biochemistry, University of Saskatchewan , 107 Wiggins Road, Saskatoon, Canada , S7N 0W0.</nlm:affiliation>
<wicri:noCountry code="subField">S7N 0W0</wicri:noCountry>
</affiliation>
</author>
</analytic>
<series><title level="j">ACS chemical neuroscience</title>
<idno type="eISSN">1948-7193</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>Molecular Conformation</term>
<term>Neuroprotective Agents (therapeutic use)</term>
<term>Neurotoxicity Syndromes (drug therapy)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Protein Binding (drug effects)</term>
<term>alpha-Synuclein (drug effects)</term>
<term>alpha-Synuclein (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>alpha-Synuclein</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>alpha-Synuclein</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Protein Binding</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neurotoxicity Syndromes</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>Molecular Conformation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The misfolding of α-synuclein is a critical event in the death of dopaminergic neurons and the progression of Parkinson's disease. Drugs that bind to α-synuclein and form a loop structure between the N- and C-terminus tend to be neuroprotective, whereas others that cause a more compact structure tend to be neurotoxic. The binding of several natural products and other drugs that are involved in dopamine metabolism were investigated by nanopore analysis and isothermal titration calorimetry. The antinausea drugs, cinnarizine and metoclopramide, do not bind to α-synuclein, whereas amphetamine and the herbicides, paraquat and rotenone, bind tightly and cause α-synuclein to adopt a more compact conformation. The recreational drug, cocaine, binds to α-synuclein, whereas heroin and methadone do not. Metformin, which is prescribed for diabetes and is neuroprotective, binds well without causing α-synuclein to adopt a more compact conformation. Methylphenidate (ritalin) binds to sites in both the N- and C-terminus and causes α-synuclein to adopt a loop conformation. In contrast, amphetamine only binds to the N-terminus. Except for cinnarizine and metoclopramide, there is a good correlation between the mode of binding to α-synuclein and whether a drug is neuroprotective or neurotoxic.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26378986</PMID>
<DateCreated><Year>2015</Year>
<Month>12</Month>
<Day>16</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>09</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>12</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1948-7193</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>6</Volume>
<Issue>12</Issue>
<PubDate><Year>2015</Year>
<Month>Dec</Month>
<Day>16</Day>
</PubDate>
</JournalIssue>
<Title>ACS chemical neuroscience</Title>
<ISOAbbreviation>ACS Chem Neurosci</ISOAbbreviation>
</Journal>
<ArticleTitle>Drugs That Bind to α-Synuclein: Neuroprotective or Neurotoxic?</ArticleTitle>
<Pagination><MedlinePgn>1930-40</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1021/acschemneuro.5b00172</ELocationID>
<Abstract><AbstractText>The misfolding of α-synuclein is a critical event in the death of dopaminergic neurons and the progression of Parkinson's disease. Drugs that bind to α-synuclein and form a loop structure between the N- and C-terminus tend to be neuroprotective, whereas others that cause a more compact structure tend to be neurotoxic. The binding of several natural products and other drugs that are involved in dopamine metabolism were investigated by nanopore analysis and isothermal titration calorimetry. The antinausea drugs, cinnarizine and metoclopramide, do not bind to α-synuclein, whereas amphetamine and the herbicides, paraquat and rotenone, bind tightly and cause α-synuclein to adopt a more compact conformation. The recreational drug, cocaine, binds to α-synuclein, whereas heroin and methadone do not. Metformin, which is prescribed for diabetes and is neuroprotective, binds well without causing α-synuclein to adopt a more compact conformation. Methylphenidate (ritalin) binds to sites in both the N- and C-terminus and causes α-synuclein to adopt a loop conformation. In contrast, amphetamine only binds to the N-terminus. Except for cinnarizine and metoclopramide, there is a good correlation between the mode of binding to α-synuclein and whether a drug is neuroprotective or neurotoxic.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kakish</LastName>
<ForeName>Joe</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Biochemistry, University of Saskatchewan , 107 Wiggins Road, Saskatoon, Canada , S7N 0W0.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Dongsoo</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Biochemistry, University of Saskatchewan , 107 Wiggins Road, Saskatoon, Canada , S7N 0W0.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Jeremy S</ForeName>
<Initials>JS</Initials>
<AffiliationInfo><Affiliation>Department of Biochemistry, University of Saskatchewan , 107 Wiggins Road, Saskatoon, Canada , S7N 0W0.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>09</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>ACS Chem Neurosci</MedlineTA>
<NlmUniqueID>101525337</NlmUniqueID>
<ISSNLinking>1948-7193</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008968" MajorTopicYN="N">Molecular Conformation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020258" MajorTopicYN="N">Neurotoxicity Syndromes</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson’s disease</Keyword>
<Keyword MajorTopicYN="N">isothermal titration calorimetry</Keyword>
<Keyword MajorTopicYN="N">nanopore analysis</Keyword>
<Keyword MajorTopicYN="N">neuroprotective drugs</Keyword>
<Keyword MajorTopicYN="N">neurotoxic drugs</Keyword>
<Keyword MajorTopicYN="N">protein folding</Keyword>
<Keyword MajorTopicYN="N">α-synuclein</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>9</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>9</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>9</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26378986</ArticleId>
<ArticleId IdType="doi">10.1021/acschemneuro.5b00172</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list></list>
<tree><noCountry><name sortKey="Kakish, Joe" sort="Kakish, Joe" uniqKey="Kakish J" first="Joe" last="Kakish">Joe Kakish</name>
<name sortKey="Lee, Dongsoo" sort="Lee, Dongsoo" uniqKey="Lee D" first="Dongsoo" last="Lee">Dongsoo Lee</name>
<name sortKey="Lee, Jeremy S" sort="Lee, Jeremy S" uniqKey="Lee J" first="Jeremy S" last="Lee">Jeremy S. Lee</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000534 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000534 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:26378986 |texte= Drugs That Bind to α-Synuclein: Neuroprotective or Neurotoxic? }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26378986" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonCanadaV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |